We next examined changes in PrPC, FOXO3a, and KLF5 expression levels during progression from primary colorectal cancer to liver metastasis in matched patient samples, to determine a signaling response to platinum‐based therapy. The gene discussed is FOXO3; the disease is colorectal cancer.